After 6 months of treatment, there were still 21% of patients having daytime symptoms more than twice a week, 7.6% having nighttime symptoms, 9.2% having limitation of activity, 19.3% using rapid acting β2 agonist more than twice a week, 32.8% having one or more exacerbations and there were 73.8% of patients having PEF or FEV1 under 80% predicted value on spirometry.